Credit Suisse analyst Vamil Divan maintained a Market Perform rating and lowered the price target for Teva shares from $26 to $20.
Teva's first-time 2019 guidance was below expectations across many metrics such as revenue, EBITDA and EPS, Divan said in a Wednesday note.
The biggest contributors to the North American generics business were generic Sensipar, Cialis, Concerta and Cubicin, the analyst said.
Teva should continue to benefit from these products as well as the potential new launches of generic Restasis, Nuvaring and Forteo this year, Divan said.
Notwithstanding the uncertainty surrounding the timing of approval for these products, Teva sees stabilization of the North American generics business at $1 billion per quarter, the anlayst said.
The 2019 product level guidance for Copaxone, Ajovy and Austedo was in-line with Credit Suisse's expectations.
Teva also guided to over 27-percent operating margins, a cash-to-earnings ratio of more than 80 percent and net debt-EBITDA at more than 3x within three to five years, Divan said.
"Although we think the sharp sell-off may be somewhat overdone and 2019 guidance could prove to be conservative, we maintain our Neutral rating as the focus shifts from a restructuring story to a growth one where our growth expectations are below that of the company."
Teva's ability to return to single-digit top-line growth in 2020 hinges on new product launches such Ajovy and biosimilar Rituxan later this year, along with a better-than-expected uptake of Austedo, the analyst said.
Credit Suisse estimates flattish growth in 2020 followed by low-single digit sales growth in 2021 and 2022.
The Price Action
Teva shares were adding to Wednesday's losses and were down 2.1 percent to $17.25 at last check Thursday.
The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial
Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Public domain photo via Wikimedia.
Latest Ratings for TEVA
|Feb 2019||Credit Suisse||Maintains||Neutral||Neutral|
|Feb 2019||Raymond James||Upgrades||Market Perform||Outperform|
View More Analyst Ratings for TEVA
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen
- The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.